CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE (CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE).
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
| Metabolism | Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally. |
| Excretion | Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally. |
| Half-life | The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours. |
| Protein binding | Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound. |
| Volume of Distribution | The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg). |
| Bioavailability | Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism. |
| Onset of Action | Oral administration: onset of bowel evacuation occurs within 1-3 hours. |
| Duration of Action | Duration of bowel cleansing effect is typically 3-6 hours post-dose; complete evacuation usually occurs within 6-8 hours. |
| Molecular Weight | Sodium picosulfate: 481.4 Da; Magnesium oxide: 40.30 Da; Citric acid: 192.12 Da |
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
| Dosage form | FOR SOLUTION |
| Renal impairment | Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). For eGFR 30-60, use with caution and ensure adequate hydration. |
| Liver impairment | No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances. |
| Pediatric use | Safety and efficacy not established in pediatric patients; not recommended for use in children. |
| Geriatric use | No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration. |
| 1st trimester | Avoid use due to insufficient safety data; potential for teratogenicity not established. |
| 2nd trimester | Use only if clearly needed; no adequate studies in pregnant women. |
| 3rd trimester | Avoid use near term due to risk of electrolyte disturbances and potential for uterine hyperstimulation. |
Clinical note
Comprehensive clinical and safety monograph for CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE (CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE).
| Placental transfer | Sodium picosulfate crosses the placenta; magnesium ions are actively transferred. Citric acid is naturally present and rapidly metabolized. |
| Breastfeeding | Sodium picosulfate is minimally excreted into breast milk. However, citric acid and magnesium oxide may cause gastrointestinal effects in the infant. Use with caution, especially in neonates with immature renal function. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed. |
| Fetal Monitoring | Monitor maternal serum electrolytes (magnesium, sodium, potassium) and renal function during prolonged use. Assess for signs of dehydration, especially in pregnant patients. Fetal heart rate monitoring not specifically required. |
| Fertility Effects | No known effects on fertility. Magnesium oxide and citric acid are not expected to impair fertility; sodium picosulfate has no reported fertility impact in animal studies. |
■ FDA Black Box Warning
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
| Serious Effects |
Known hypersensitivity to any componentGastrointestinal obstructionAcute surgical abdomenSevere dehydrationRenal failure (creatinine clearance < 30 mL/min)Toxic megacolonPhenylketonuria (contains phenylalanine in some formulations)
| Precautions | Do not use in patients with gastrointestinal obstruction, perforation, or ileus., Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance., Monitor for fluid and electrolyte disturbances., Avoid use in patients with known hypersensitivity to any component. |
| Food/Dietary | Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products. |
| Clinical Pearls | Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease. |
| Patient Advice | Take this medication exactly as prescribed to prepare your colon for a procedure. · Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration. · You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins. · Do not take any other laxatives or stool softeners while using this product unless directed by your doctor. · Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling). · This medication will cause frequent, watery bowel movements; stay near a bathroom. |
Loading safety data…